SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen® BioSciences, Inc., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today announced the results of a bone marrow study involving Homspera. Results point to the ability of Homspera to enhance formation of early-stage blood cells from adult hematopoietic (blood-forming) stem cells. The studies, performed by University of Medicine and Dentistry of New Jersey (UMDNJ) Professor Pranela Rameshwar, Ph.D, not only were consistent with previous stem cell study results, but also demonstrated the potency of Homspera.
